Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CATX · NYSE · Pharmaceutical Preparations
Perspective Therapeutics (CATX) · oqro.io/stocks/CATX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.9431+0.1007 (+11.95%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Perspective Therapeutics (CATX) filed 3 open-market purchases in the last 90 days; the latest was filed on Nov 13, 2026.
Since 2006, Perspective Therapeutics insiders reported 198 open-market purchases and 11 sales on Forms 4 and 5, with purchases in 18 different years, most recently 2026.
No open-market sale by an insider of Perspective Therapeutics (CATX) was filed with the SEC in the last 90 days.
No trade in Perspective Therapeutics (CATX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−54.4% (−$1.13) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $2.07 on Nov 13, 2025 to $0.9431 on Nov 13, 2026 (−54.4%). Disclosed in this range: 3 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Seattle, Wa.
Last 12 months
−54.4%
Market value
$108M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 8.97M shares sold short (7.9% of shares outstanding), −46.2% vs the previous count, 2.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
−$121M
This quarter −$34.8M, a year earlier −$21M
Net cash
$46.9M
Debt $1.6M, cash $48.5M, at Jun 30, 2026
Net income, last 12 months
−$116M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
Traded Nov 11 – Nov 12, 2026 · largest single transaction ~$30K
Nov 12, 2026~$30K · 35K sh @ $0.8447
Nov 11, 2026~$5K · 6,000 sh @ $0.83
DetailsOfficial recordInsider buying
First insider buy since Mar 2025Traded Nov 11 · filed 1 day later
Since the trade +14.3% · S&P 500 −0.7% · to Nov 13
The CEO of Perspective Therapeutics paid $38K out of pocket for Perspective Therapeutics shares. 1 other person at Perspective Therapeutics bought some too, in the same month. It was the first purchase in 20 months.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider buying
Traded Mar 28, 2025 · filed 4 days later
Since the trade −57.1% · S&P 500 +35.8% · to Nov 13
The CFO of Perspective Therapeutics paid $75K out of pocket for Perspective Therapeutics shares. 3 other people at Perspective Therapeutics bought some too, in the same month. Shares held went up 1649% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
2 certified in FY2026 Q3, vs 2 a year earlier. 2 positions in total, median offered wage $128K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Insiders of Perspective Therapeutics reported 198 open-market purchases and 11 sales since 2006; purchases in 18 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $72K3×3 trades | — |
| 2025 | $317K6×6 trades | — |
| 2024 | $58.4M37×37 trades | — |
| 2023 | $279K9×9 trades | — |
| 2022 | $106K8×8 trades | — |
| 2020 | $145K9×9 trades | — |
| 2019 | $83K4×4 trades | — |
| 2018 | $108K11×11 trades | — |
| 2017 | $69K38×38 trades | — |
| 2016 | $96K7×7 trades | — |
| 2015 | $97K10×10 trades | $20K1×1 trade |
| 2014 | — | $188K3×3 trades |
| 2013 | $13K1×1 trade | — |
| 2012 | $50K16×16 trades | $11K2×2 trades |
| 2011 | $64K12×12 trades | $23K4×4 trades |
| 2009 | $9.5K2×2 trades | — |
| 2008 | $49K14×14 trades | — |
| 2007 | $109K10×10 trades | — |
| 2006 | $29K1×1 trade | $117K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 3 active phase 2 trials led by this company, mostly in recurrent melanoma (skin), pancreatic ductal adenocarcinoma, neuroendocrine tumors unresectable. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Fails to deliver: 695K shares (about $2M) were not delivered on time for settlement on Sep 21, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Last results
Nov 9, 2026
Within the 30 days after it, until Dec 9, 2026
Next results, expected
Not announced
Purchases after results
84%
167 of 198 insider purchases since 2006 came within 30 days after a results announcement
From Perspective Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Perspective Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
On the public record for Perspective Therapeutics over the 12 months to Nov 14, 2026: 3 clinical trials.
